[CONSTRUCTION OF A TEST-SYSTEM WITH NANOPARTICLES OF COLLOID SILVER FOR DETECTION OF PSEUDOTUBERCULOSIS AND INTESTINAL YERSINIOSIS FOR CAUSATIVE AGENTS IN DOT-IMMUNOASSAY].

Aim: Construction of an immunologic test-system for detection of causative agents of enteropathogenic Yersinia (Yersinia pseudotuberculosis and Y. enterocolitica) by dot-immunoassay.

Materials And Methods: Nenoparticles of colloid silver sized 5-9 nm were used as a marker of specific antibodies.

[The diagnostic of defects of inborn immunity under B-cell tumors of lymphatic system].

The genetic characteristics are key risk factors of development of many human neoplasms including B-cell tumors of lymphatic system. The relationship between polymorphic variants of genes FCGR2A (His 1 66Agr), CD14 (C-159T). IL1β (T-31C), IL2 (7:330G) and 7LR2 (Arg753Ghn) and development of various forms of B-cell tumors of lymphatic system in 80 patients was investigated.

Role of glutathione-S-transferase M1 (GSTM1) and T1 (GSTT1) genes in the development and progress of chronic myeloid leukemia and in the formation of response to imatinib therapy.

The effects of GSTM1 and GSTT1 gene deletion ("zero") polymorphisms on the risk of chronic myeloid leukemia development and progress and on response to imatinib monotherapy were studied in the representatives of the Russian nationality in the Vyatka region of Russia. Homozygotic carriership of GSTT1 "zero" allele was associated with a 3.66 times higher risk of chronic myeloid leukemia development in residents of the Vyatka region (OR=3.

[The interpretation of immunophenotyping results during diagnostics of lymphatic proliferative disease using immunophenotyping count].

The article considers immune phenotyping heterogeneity of chronic lymphatic leukemia detected using basic diagnostic markers ofcell. The results of analysis of immune phenotypes of 108 patients with B-cell lymphatic proliferative diseases made it possible to establish that the atypical is related most rarely to indicators of expression of monotypic immunoglobulines and CD5 and most frequently to CD23, FMC7, CD22 and CS79b. During the present observation, the immune phenotyping count made up "3" or "2"points and the atypical alternative was registered among 10% of all examined patients with chronic lymphatic leukemia.

[The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].

Aim: To give the preliminary results of the AML-01.10 Russian multicenter randomized trial to treat adult acute myeloid leukemia (AML), the basic principle of which is to use high-dose anthracycline antibiotics in induction/consolidation.

Subjects And Methods: By December 2011, 145 patients with AML had been randomized from 18 hematology centers of 15 cities and towns of the Russian Federation; the median age of all the patients was 44 years.

[Toxicity of different treatment protocols for acute myeloid leukemias in adults: the results of four Russian multicenter studies].

Aim: To comparatively analyze the toxicity of 4 treatment protocols in patients with acute myeloid leukemia (AML), which were used in the Russian multicenter center in 1992 to 2009.

Materials And Methods: The information obtained in 4 Russian multicenter studies conducted in 33 hematology departments of 26 cities and towns of the Russian Federation in 1992 to 2009 was analyzed. Randomization was made in 243 patients with AML (median age 38 years) in 1992-1995, 396 patients (median age 39 years) in 1995-1999, 392 patients (median age 39 years) in 2001-2006, and 137 patients (median age 40 years) in 2006-2009.

[Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].

Aim: to analyze the efficacy of RFC (rituximab, fludarabine, and cyclophosphan), FCM (fludarabine, cyclophosphan, and mitoxantrone), and FC (fludarabine and cyclophosphan) treatment programs in patients with chronic lymphocytic leukemia (CLL) in an open-labeled comparative controlled investigation.

Materials And Methods: The paper presents the authors' results of treatment in patients with progressive CLL in 2002 to 2007. The study included 229 patients, of them 78 patients received the RFC program, 72 had the FCM program, and 79 had the FC one.

[Results of the treatment of adult acute lymphoblastic leukemia according to ALL-2005 protocol as a basis for new trials].

Aim: To analyse the results of the treatment according to ALL-2005 protocol for adult patients with acute lymphoblastic leukemia (ALL); on the basis of the summarized evidence on ALL treatment to propose principles for development of a new program of ALL treatment in 15-55-year-old patients.

Material And Methods: Five hematological centers (in Moscow, Saransk, Volgograd, Tambov, Kirov) participated in ALL-2005 protocol trial initiated in 2005. A total of 71 adult patients with ALL (age median 27 years) were treated.

[The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults].

Aim: Systematization of the results of 20-year multicenter randomized trial of the efficacy of treatment of acute myeloid leukemia (AML) of adults; presentation of the design of the study of the strategy of consolidation and maintenance therapy after high-dose consolidation initiated in 2007.

Material And Methods: Treatment outcomes on the protocol AML-01.01 are presented for 354 AML patients from 29 hematological centers located in 22 towns of Russia and 2 towns of Ukraine.

[Preliminary results of a multicenter randomized study on the treatment of acute promyelocytic leukemias].

Aim: To study efficacy of maintenance therapy of patients with acute promyelocytic leukemia (APL) in the APL treatment Russian multicenter trial.

Material And Methods: The trial was made with participation of 18 hematological departments of clinics in Russia. A total of 68 APL patients entered the trial.

[Dot immunoassay with colloidal silver particles as a marker of specific antigen for testing human sera for brucellosis].

Whether the dot immunoassay is suitable for the detection of Brucella antibodies in human sera by using a colloidal silver-labeled Brucella specific antigen as a diagnostic tool is assessed. The antigen was the B. abortus 19BA protein polysaccharide complex isolated by Brucella acetic acid hydrolysis.

[Use of specific antibodies labelled with colloid silver particles for detection of Brucella antigens with dot immune analysis].

Fitness of dot immuno-analysis for detection of Brucella antigens labeled with colloid silver is evaluated. Soluble lipopolysaccharides and protein-saccharide antigen and corpuscular antigens of 22 Brucella strains (7 species) pathogenic for humans and animals in the S and R forms were used. The specificity of the method was tested on 10 heterologous microorganisms whose antigens were closely related.

[Detection of brucella antigens with colloid metal particles as markers for specific antigens].

Gold and silver sols were comparatively approved as markers of specific IgG isolated from hyperimmune Brucella antisera for the detection of brucellar antigens. The sensitivity of the test system using gold immunosol proved to be some higher (3.1-9.

[Detection of Brucella antigens by dot immunoassay using specific antibodies labelled with colloid gold particles].

Dot immunoassay was developed to improve the quality of laboratory diagnosis of brucellosis. Particles of colloid gold were used as a marker of specific antibodies. The method was used for detecting Brucella antigens in artificially contaminated environmental objects (soil and water) and in biological material (milk, blood serum, and visceral homogenates of animals).

[Use of protein-polysaccharide Brucella antigen labeled with colloidal gold for detection of specific antibodies by the dot-immunoassay method].

Antibrucella antibodies were detected by dot-immunoassay with colloid gold label of antigen. The specific antigen was protein-polysaccharide complex (PPC) isolated from vaccine strain Brucella abortus 19 BA by acetic acid hydrolysis of bacterial cells. Dot immunoassay with PPC labeled with colloid gold was effective in testing cattle, rabbit, and human sera for antibrucella antibodies.

[Use of specific antibodies, labeled with colloidal gold particles, for the detection of Brucella antigens using dot-immunoassay].

The method of dot immunoassay with the use specific antigens, labeled with colloidal gold particles, for the detection of brucellar antigens was developed and tested under laboratory and field conditions. In this work soluble antigens isolated from different Brucella species and corpuscular antigens (13 strains belonging to 7 species of the genus Brucella, most pathogenic for humans and animals in the S- and R-forms) were used. The method was tested in the study of pathological material obtained from sick animals and humans in a farm with unfavorable situation for brucellosis in the Irkutsk Region.